 | Up a level |
Harrison, Claire, Andreasson, Bjorn, Cambier, Nathalie, Gerds, Aaron, Grosicki, Sebastian, Illes, Arpad, Kiladjian, Jean-Jacques, Lavie, David, Mesa, Ruben, Palmer, Jeanne, Passamonti, Francesco, Perkins, Andrew, Sacha, Tomasz, Scheid, Christof, Todorieva-Todorova, Doroteya, Vannucchi, Alessandro, Wozny, Tomasz, Klencke, Barbara, Kowalski, Mark and Verstovsek, Srdan (2020). Long-Term Safety of Momelotinib in JAK Inhibitor-Naive and Previously JAK Inhibitor-Treated Intermediate-/High-Risk Myelofibrosis Patients. Clin. Lymphoma Myeloma Leuk., 20. S. S330 - 2. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669
Harrison, Claire N., Egyed, Miklos, Szoke, Anita, Suvorov, Aleksandr, Perkins, Andrew 
ORCID: 0000-0003-3644-7093, Mayer, Jiri, Ganly, Peter, Schouten, Harry C., Tosi, Patrizia, Farber, Charles Michael, Zachee, Pierre, Scheid, Christof, Dean, James P., Zhou, Huafeng, Kiladjian, Jean -Jacques, Vannucchi, Alessandro M., Nangalia, Jyoti, Mead, Adam and Mesa, Ruben A.
(2016).
Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.
J. Clin. Oncol., 34 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Harrison, Claire N., Egyed, Miklos, Szoke, Anita, Suvorov, Aleksandr, Perkins, Andrew ORCID: 0000-0003-3644-7093, Mayer, Jiri, Ganly, Peter, Schouten, Harry C., Tosi, Patrizia, Farber, Charles Michael, Zachee, Pierre, Scheid, Christof, Dean, James P., Zhou, Huafeng, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Nangalia, Jyoti, Mead, Adam and Mesa, Ruben A.
(2016).
Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy.
J. Clin. Oncol., 34 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Mesa, Ruben A., Egyed, Miklos, Szoke, Anita, Suvorov, Aleksandr, Perkins, Andrew ORCID: 0000-0003-3644-7093, Mayer, Jiri, Ganly, Peter, Jourdan, Eric, Schouten, Harry C., Tosi, Patrizia, Farber, Charles Michael, Zachee, Pierre, Scheid, Christof, Dean, James P., Cernohous, Paul, Nangalia, Jyoti, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Mead, Adam and Harrison, Claire N.
(2015).
Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).
J. Clin. Oncol., 33 (18).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Mesa, Ruben A., Egyed, Miklos, Szoke, Anita, Suvorov, Aleksandr, Perkins, Andrew ORCID: 0000-0003-3644-7093, Mayer, Jiri, Ganly, Peter, Schouten, Harry C., Tosi, Patrizia, Farber, Charles Michael, Zachee, Pierre, Scheid, Christof, Dean, James P., Granston, Tanya, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Nangalia, Jyoti, Mead, Adam and Harrison, Claire N.
(2016).
Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.
J. Clin. Oncol., 34 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Verstovsek, Srdan, Chen, Chih-Cheng, Egyed, Miklos, Ellis, Martin, Fox, Laura, Goh, Yeow T., Gupta, Vikas ORCID: 0000-0002-1419-8607, Harrison, Claire, Kiladjian, Jean-Jacques ORCID: 0000-0002-8121-438X, Lazaroiu, Mihaela C., Mead, Adam, McLornan, Donal, McMullin, Mary F., Oh, Stephen T., Perkins, Andrew, Platzbecker, Uwe, Scheid, Christof, Vannucchi, Alessandro, Yoon, Sung-Soo, Kowalski, Mark M. and Mesa, Ruben A.
(2021).
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Future Oncol., 17 (12).
S. 1449 - 1459.
LONDON:
FUTURE MEDICINE LTD.
ISSN 1744-8301